http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
임상 : 악성뇌교종의 항암 및 방사선 병합치료의 효과와 독성
임동환 ( Dong Hwan Lim ),전신수 ( Shin Soo Jeun ),박춘근 ( Chun Geun Park ),강준기 ( Joon Gi Kang ),김문찬 ( Moon Chan Kim ),홍용길 ( Yong Kil Hong ) 대한뇌종양학회 2005 대한뇌종양학회지 Vol.4 No.1
Objective£ºConcurrent chemotherapy and radiotherapy trials have been reported to increase anti-tumoral effect and toxicity in several solid cancers, but little has been known in brain tumors. We analyzed clinical efficacy and toxicity of the concurrent therapy as a first line modality in malignant glioma patients. Methods£ºFrom March 1998 to December 2003, twenty- five patients were enrolled in this study. They are composed of 11 glioblastomas(GBM), 8 anaplastic astrocytomas(AA), 5 anaplastic oligodendrogliomas(AO), and 1 anaplastic oligoastrocytoma(AOA). Mean age was 45.3(19-67) years old with 14 females and 11 males. Both radiotherapy and chemotherapy, composed of BCNU(120mg/m2) or CCNU(75-110mg/m2), procarbazine(60mg/m2) and vincristine(1.4 mg/m2), started simultaneously within 2 weeks after surgery. Results£ºMedian progression-free survival time(PFS) was 9 months for the patients with GBM, and 19 months for the patients with Non-GBM. Grade III/IV leukopenia developed in 7 of 25(28%) patients and thrombocytopenia in 2 of 25 (8%). Radiation necrosis occurred in 3 patients(12%). Conclusion£ºConcurrent chemoradiotherapy improved PFS in high-grade glioma patients and its toxicity was tolerable. These preliminary results suggest that further studies would be warranted to improve the clinical efficacy of this therapy in malignant gliomas.
뇌졸중 쥐 모델에서 인간 제대혈 유래 중간엽줄기세포의 치료 효과 연구
정창현 ( Chang Hyun Jeong ),임정연 ( Jung Yeon Lim ),박상인 ( Sang In Park ),김성묵 ( Seong Muk Kim ),전진애 ( Jin Ae Jun ),오원일 ( Won Il Oh ),이재권 ( Jae Kwon Lee ),전신수 ( Shin Soo Jeun ) 한국조직공학과 재생의학회 2006 조직공학과 재생의학 Vol.3 No.4
Mesenchymal stem cells(MSCs) have the ability to differentiate into multiple cell types. It has been reported that MSCs ameliorate functional deficits after transplantation into various neurologic disease models. In this study, to demonstrate the effect of human umbilical cord blood-derived MSCs(hUCB-MSCs) on stroke models, we transplanted the PKH-26 labeled hUCB-MSCs into the contralateral region of injured rat brain at 7 days after injury, and then examined the behavioral test, migration ability of transplanted hUCB-MSCs to injury site, and differentiation potentiality of transplanted hUCB-MSCs into neural cells. The results were: (1) a behavioral test(adhesive- removal and rotarod test) showed a significant improvement in the MSCs transplanted group as compared to the PBS injected group, (2) PKH-26 labeled MSCs were detected in the boundary zone of injured site at 4 weeks after transplantation, and (3) a few of transplanted MSCs exhibited a labeling for mature neural linage markers NeuN and GFAP. We suggest that hUCB-MSCs could be an effective cell source for treating ischemic brain injury.